At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...

Today’s announcement (August 20) on draft guidelines from the UK’s National Institute for Health and Care Excellence (NICE) ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

GPs could face a rise in prescribing and monitoring work under draft NICE guidelines recommending earlier use of newer type 2 ...

The NHS should move away from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...

AstraZeneca's Farxiga (dapagliflozin) for diabetes, heart failure, and chronic kidney disease – down 68% to $178.50; Immunex's Enbrel (aflibercept) for rheumatoid arthritis, psoriasis, and ...